Sign in
CompletedNo phase

Myoinositol vs. Metformin for Polycystic Ovarian Syndrome (PCOS): Impact on Metabolic Health and Fertility

Key facts

Who runs it
Benha University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
156 people enrolled
Started
25 Nov 2024
Ended
18 Jun 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Metformin Hydrochloride 500 MG
  • Myoinositol
Record updated
10 July 2025

Who can take part

Age
23 years to 47 years
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients presenting manifestations suggestive of having PCOS
  • Patients were free of exclusion criteria

Who cannot take part

  • Patients who were on medical therapy of PCOS, antidiabetic or/and antihypertensive therapy
  • Patients with dyslipidemia, hereditary lipoprotein disorders:
  • Patients with chronic liver or kidney diseases
  • Patients who were maintained on a diet regimen, or/and regular exercise
  • Patients who underwent laparoscopic drilling

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study aimed to assess how a 6-month insulin sensitizer therapy impacts insulin resistance, glucose tolerance, and hormonal levels in women with PCOS. Researchers evaluated 156 PCOS patients, measuring their BMI, HOMA-IR (for insulin resistance), TyG index, TyG index-BMI, and total testosterone. Participants were divided into two groups, receiving either metformin or a myoinositol/d-chiro-inositol combination for six months, after which all parameters were re-evaluated to determine the percentage of change.

The 2 groups in the trial

  • Myoinositol GroupExisting treatment, for comparison

    Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took the tablets containing myoinositol/d-chiro-inositol combination (MYO/DCI) in 40:1 ratio

    Treatment: Myoinositol

  • Metformin GroupExisting treatment, for comparison

    Patients presenting manifestations suggestive of having PCOS were evaluated for enrollment in the study, and took metformin (MET) hydrochloride 500 mg

    Treatment: Metformin Hydrochloride 500 MG

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Myoinositol Therapy May Adjust The Metabolic Deregulation in Infertile Polycystic Ovarian Syndrome (PCOS) Women Through Modulation of The TyG Index-BMI: A Comparative Study Versus Metformin
Record updated
10 July 2025